Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially...